A new nasal spray vaccine against whooping cough enters a clinical study in the country, as announced by the Metropolitan Hospital, who added that it will be from the Metropolitan Research Institute (MRI) that its relevance will be evaluated.
Read more: Hospital Metropolitano tests the efficiency of a new drug in patients with lung cancer
“Whooping cough, a highly contagious respiratory disease caused by the Bordetella pertussis bacterium, represents a significant threat to infants under one year of age, pregnant women, people with chronic respiratory diseases, and older adults,” said Gabriela Ivankovich, pediatric immunologist and MRI principal investigator at Hospital Metropolitano.
In 2019, more than 145,000 cases of whooping cough were reported worldwide, which underscores the importance of prevention and the need for a more effective vaccine, so this new drug seeks to prevent people from contracting the disease or passing it on to others.
Read more: These are the vaccines that older adults should receive
The transmission of whooping cough to babies under one year of age occurs mainly through their parents and siblings, so the population between 12 and 18 years of age becomes an important source of infection.
Currently, in Costa Rica, the last booster of the vaccine is administered between four and six years, but its effectiveness decreases over time, which is why attention must be paid to the symptoms to prevent contagion.
“The vaccine currently used in the national immunization program, known as Boostrix®, provides antibodies in the blood to protect against severe disease, but does not prevent infection or transmission of the bacteria to other people. Also, their protection is short-lived,” Ivankovich explained.
2023-07-24 22:00:00
#Hospital #Metropolitano #leads #research #whooping #cough #vaccine
 "Roman Kukumberg’s Ambitions and Journey to the NHL Draft")
